IGF2BP1 and neuroblastoma: Though knockdown or inhibition of IGF2BP1 has been shown to sensitize melanoma to some chemotherapeutic agents and targeted therapy (25–27), its role as a potential therapeutic target in treating neuroblastoma has not been investigated.